Metamizol Stada (Metamizole Sodium Monohydrate)

Metamizole, the active ingredient in Metamizol Stada, is a pyrazolone derivative presented as an oral formulation for systemic use. It is employed to relieve mild to moderate pain, reduce fever, and manage postoperative discomfort and colic in adult patients. GNH USA supplies Metamizol Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Metamizole acts as a non‑opioid analgesic and antipyretic, targeting pain and fever pathways. - Mild to moderate pain: provides effective relief when other analgesics are insufficient. - Fever: reduces elevated body temperature in acute febrile states. - Post‑operative pain: helps control discomfort after surgical procedures. - Colic: alleviates visceral pain associated with intestinal or biliary colic.

Metamizole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: transient gastrointestinal upset. - Vomiting: occasional emesis following dose. - Dizziness: mild vertiginous sensation. - Hypotension: transient drop in blood pressure, especially with rapid administration. - Skin rash: mild erythematous eruption.

Serious or Rare Side Effects: - Agranulocytosis: severe reduction in neutrophils, potentially life‑threatening. - Anaphylactic reaction: rapid onset of airway swelling and hypotension. - Stevens‑Johnson syndrome: severe mucocutaneous blistering. - Hemolytic anemia: destruction of red blood cells. - Hepatic dysfunction: elevated liver enzymes indicating liver injury.

Metamizole should be used with caution and under medical supervision. - Blood count monitoring: perform baseline and periodic leukocyte counts to detect agranulocytosis early. - Hypersensitivity avoidance: do not use in patients with known allergy to pyrazolones. - Renal/hepatic impairment: adjust use and monitor organ function. - Pregnancy and lactation: avoid unless benefits outweigh potential risks. - Concomitant myelosuppressants: increase risk of bone‑marrow suppression. - Store at ambient temperature: keep in the original pack, protect from moisture.

Metamizole can interact with several drug classes, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid): - Other myelosuppressive agents: heightened risk of agranulocytosis. - Known hypersensitivity to other pyrazolone derivatives: may trigger severe allergic response.

Moderate Interactions (Monitor Closely): - NSAIDs (e.g., ibuprofen, diclofenac): may diminish analgesic efficacy. - ACE inhibitors or diuretics: potential additive hypotensive effect. - Alcohol: can exacerbate dizziness and hypotension. - Anticoagulants (e.g., warfarin): possible increase in bleeding tendency.